![]() ![]() Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Tracking the evolution of non-small-cell lung cancer. EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Overall survival with osimertinib in untreated, EG FR-mutated advanced NSCLC. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Amino acid sequences indicators of evolution plus#Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |